Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00573391 |
| Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 |
| terminated |
| Phase 3 |
| 5 |
| University of ArkansasOTHER |
| 1 |
| Aug 12, 2011 |
| clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT01296503 | Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | completed | Phase 3 | 213 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00602511 | Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | completed | Phase 3 | 300 | Nordic Myeloma Study GroupOTHER | 3 | Feb 9, 2011 | clinicaltrials |
| NCT00083876 | D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 500 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00093028 | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | completed | Phase 3 | 315 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00417911 | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | completed | Phase 3 | 400 | Nordic Myeloma Study GroupOTHER | 5 | Jun 22, 2010 | clinicaltrials |
| NCT01016548 | Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy | completed | Phase 3 | 42 | University Health Network, TorontoOTHER | 1 | Jun 4, 2010 | clinicaltrials |
| NCT00222053 | IFM 99-02 Thalidomide in Myeloma | completed | Phase 3 | 800 | University Hospital, ToulouseOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00179647 | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 1,913 | Celgene CorporationINDUSTRY | 2 | Mar 16, 2010 | clinicaltrials |
| NCT01085058 | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) | completed | Phase 2 / Phase 3 | 169 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Mar 11, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 | clinicaltrials |
| NCT00571168 | Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy(EmNa) | unknown | Phase 3 | 362 | Heidelberg UniversityOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00932217 | Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma | unknown | Phase 3 | 180 | University of PisaOTHER | 0 | Jul 3, 2009 | clinicaltrials |
| NCT00910897 | Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | unknown | Phase 3 | 205 | Intergroupe Francophone du MyelomeNETWORK | 2 | Jun 1, 2009 | clinicaltrials |
| NCT00083564 | Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma | terminated | Phase 3 | 240 | Poniard PharmaceuticalsINDUSTRY | 2 | Mar 31, 2009 | clinicaltrials |
| NCT00872352 | Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients | unknown | Phase 3 | 30 | Wolfson Medical CenterOTHER_GOV | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 26, 2009 | clinicaltrials |
| NCT00200681 | IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | completed | Phase 3 | 493 | Nantes University HospitalOTHER | 1 | Feb 5, 2009 | clinicaltrials |
| NCT00207805 | The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma | completed | Phase 3 | 202 | Centre National de Greffe de Moelle OsseuseOTHER_GOV | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00560053 | Pethema Multiple Myeloma 2000 | completed | Phase 3 | 500 | PETHEMA FoundationOTHER | 0 | Nov 27, 2008 | clinicaltrials |
| NCT00415987 | Hematopoietic Stem Cell Transplantation in Myeloma | unknown | Phase 2 / Phase 3 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00644306 | Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma(IFM 01/01) | terminated | Phase 3 | 232 | Central Hospital, Nancy, FranceOTHER | 1 | Mar 26, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00546988 | Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years | unknown | Phase 3 | 600 | University of WuerzburgOTHER | 2 | Oct 19, 2007 | clinicaltrials |
| NCT00001561 | Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation | completed | Phase 3 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2007 | clinicaltrials |
| NCT00145652 | Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | completed | Phase 3 | 66 | Sundsvall HospitalOTHER | 1 | Jul 30, 2007 | clinicaltrials |
| NCT00376883 | Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month | completed | Phase 3 | 500 | Nordic Myeloma Study GroupOTHER | 3 | Jan 4, 2007 | clinicaltrials |
| NCT00037791 | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | completed | Phase 3 | 180 | PfizerINDUSTRY | 3 | Nov 9, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00378222 | Autologous Transplantation for Multiple Myeloma | completed | Phase 3 | 324 | University of BolognaOTHER | 0 | Sep 19, 2006 | clinicaltrials |
| NCT00367185 | Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma | completed | Phase 3 | 500 | University Hospital, LilleOTHER | 1 | Aug 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Oct 10, 2011source: clinicaltrials